Celebrex, NSAID Labeling Must Be Updated Within Three Months, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's labeling template calls for Pfizer's Celebrex and other prescription NSAIDs to add "black box" warnings on cardiovascular and gastrointestinal risks. FDA is also requiring a warning on skin reactions. The agency issues a medication guide for all NSAIDs.
You may also be interested in...
Mobic Labeling Revision Includes Class Risk Language
Boehringer Ingelheim’s addition of cardiovascular and gastrointestinal risk information to Mobic labeling coincides with FDA approval of a juvenile rheumatoid arthritis indication for meloxicam.
Mobic Labeling Revision Includes Class Risk Language
Boehringer Ingelheim’s addition of cardiovascular and gastrointestinal risk information to Mobic labeling coincides with FDA approval of a juvenile rheumatoid arthritis indication for meloxicam.
Celebrex Label Adds Cardiovascular Risk Language
Celecoxib labeling revision includes long-term safety data from three celecoxib trials, one of which suggests increased cardiovascular risk. Celebrex also gains ankylosing spondylitis indication.